All In Biotech

Drug Trial Radar · NCT02796677

AMPLIFY - D6571C00001 Duaklir USA Phase III Study

A 24 Week Treatment, Multicenter, Randomized, Double Blinded, Double Dummy, Parallel-group, Clinical Trial Evaluating the Efficacy and Safety of Aclidinium Bromide 400 μg/Formoterol Fumarate 12 μg Fixed-dose Combination BID Compared With Each Monotherapy (Aclidinium Bromide 400 μg BID and Formoterol Fumarate 12 μg BID) and Tiotropium 18 μg QD When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.

Last checked: Nov 19, 2026Latest source record: Nov 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,595 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,595

Actual

Start

Jul 5, 2016

Primary completion

Jun 8, 2017

Study completion Jun 8, 2017

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400μg/Formoterol Fumarate (AB/FF) 12 μg compared to individual components and TIO (Tiotropium) 18 μg when administered to patients with stable chronic obstructive pulmonary disease (COPD).

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)Drug

    Inhalation powder

  • Aclidinium bromide 400 μg (AB 400 μg)Drug

    Inhalation powder

  • Formoterol fumarate 12 μg (FF 12 μg)Drug

    Inhalation powder

  • Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μgOther

    Inhalation powder

  • Tiotropium 18 μg (TIO 18 μg)Drug

    Powder in capsules for oral inhalation

  • Placebo to TIO 18 μgOther

    Powder in capsules for oral inhalation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in 1-hour Morning Post-dose Dose Forced Expiratory Volume in 1 Second (FEV1) of AB/FF 400/12 μg Compared to AB 400 μg at Week 24Time frame: At baseline 1-hour postdose and Week 24
  2. Change From Baseline in Morning Predose (Trough) FEV1 of AB/FF 400/12 μg Compared to FF 12 μg at Week 24Time frame: At baseline morning predose and Week 24
  3. Change From Baseline in Morning Predose (Trough) FEV1 at Week 24 Comparing AB 400 μg Versus TIO 18 μg to Demonstrate Non-inferiorityTime frame: At baseline morning predose and Week 24

Locations

163 sites in 10 countries. Site status is shown where the registry gives one.

  • Research Site

    Gulf Shores, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Corona, California

  • Research Site

    Fresno, California

  • Research Site

    Fullerton, California

  • Research Site

    Lincoln, California

  • Research Site

    San Diego, California

  • Research Site

    Waterbury, Connecticut

  • Research Site

    Clearwater, Florida

  • Research Site

    Edgewater, Florida

  • Research Site

    Hollywood, Florida

  • Research Site

    Homestead, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Miami Lakes, Florida

  • Research Site

    Ormond Beach, Florida

  • Research Site

    Port Orange, Florida

  • Research Site

    Sarasota, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Winter Park, Florida

  • Research Site

    Blue Ridge, Georgia

  • Research Site

    Woodstock, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Portage, Indiana

  • Research Site

    Lafayette, Louisiana

  • Research Site

    Fall River, Massachusetts

  • Research Site

    Chelsea, Michigan

  • Research Site

    Farmington Hills, Michigan

  • Research Site

    Troy, Michigan

  • Research Site

    Edina, Minnesota

  • Research Site

    Fridley, Minnesota

  • Research Site

    Minneapolis, Minnesota

  • Research Site

    Woodbury, Minnesota

  • Research Site

    Saint Charles, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    Fremont, Nebraska

Showing 40 of 163 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.